Hamdan Medical Journal (previously the Journal of Medical Sciences)

Table of Contents  

Islet Transplantation in Bone Marrow

Lorenzo Piemonti
Published in : Journal of Medical Sciences ; Vol 3, No 1 (2010)
DOI : 10.2174/1996327001003010035

Abstract


Islet transplantation can be an important ther-apeutic option for adults with unstable type 1 diabetes-individuals who, despite their best efforts, have wide, unpredictable fluctuations in blood sugar levels or who are no longer able to sense that their blood sugar is dangerously low. For these people, transplantation may be a viable solution. Since the first report of successful pancreatic islet transplantation to reverse hyperglycaemia in diabetic rodents, there has been great interest in determining the optimal site for implantation. Although the portal vein remains the most frequently used site clinically, it is not ideal. About half of the islets introduced into the liver die during or shortly after transplantation. Complications associated with intraportal islet injection and the progressive functional decline of intrahepatic islets encourage the exploration of alternative sites. In tests in animals, scientists from the Diabetes Re-search Institute in Milan showed that bone marrow is a promising alternative site for islet transplantation. This review considers bone marrow as site of islet transplantation and metabolic, immunological and technical aspects are discussed.

View article in  :   PDF    

References


Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007; 167: 1145-51.

Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-23.

Robertson RP, Davis C, Larsen J, Stratta R,Sutherland DE. Pancreas and islet transplantation for patients with diabetes. Diabetes Care 2000; 23:112-6.

Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-8.

Shapiro AM, Ricordi C, Hering BJ, Auchincloss H,Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-30.

Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51:2148-57.

Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-9.

Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia 1973; 9: 486-91.

Najarian JS, Sutherland DE, Baumgartner D, Burke B, Rynasiewicz JJ, Matas AJ, et al. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg 1980;192: 526-42.

Sutherland DE, Matas AJ, Goetz FC, Najarian JS.Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes 1980; 29(Suppl 1): 31-44.

Largiadèr F, Kolb E, Binswanger U. A long-term functioning human pancreatic islet allotransplant.Transplantation 1980; 29: 76-7.

Scharp DW, Lacy PE, Santiago JV, McCullough CS,Weide LG, Falqui L, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990; 39: 515-8.

Yasunami Y, Kojo S, Kitamura H, Toyofuku A, Satoh M, Nakano M, et al. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med 2005; 202: 913-8.

Toyofuku A, Yasunami Y, Nabeyama K, Nakano M,Satoh M, Matsuoka N, et al. Natural killer T-cells participate in rejection of islet allografts in the liver of mice. Diabetes 2006; 55: 34-9.

Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B,Permert J, et al. Optimising islet engraftment is critical for successful clinical islet transplantation.Diabetologia 2008; 51: 227-32.

Carlsson PO, Palm F, Andersson A, Liss P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 2001; 50: 489-95.

Al-Jazaeri A, Xu BY, Yang H, Macneil D, Leventhal JR, Wright JR Jr. Effect of glucose toxicity on intraportal tilapia islet xenotransplantation in nude mice. Xenotransplantation 2005; 12: 189-96.

Desai NM, Goss JA, Deng S, Wolf BA, Markmann E,Palanjian M, Shock AP, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 2003; 76: 1623-25.

Gupta V, Wahoff DC, Rooney DP, Poitout V, Sutherland DE, Kendall DM, et al. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 1997; 46:28-33.

Yin D, Ding JW, Shen J, Ma L, Hara M, et al. Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant 2006; 6:60-8.

Barshes NR, Wyllie S, Goss JA. Inflammationmediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol 2005; 77: 587-97.

Sudo T, Hiyama E, Murakami Y, Yokoyama Y,Takesue Y, Sueda T. Hepatic regeneration promotes engraftment of intraportally transplanted islet cells. Surgery 2005; 137: 612-9.

Bhargava R, Senior PA, Ackerman TE, Ryan EA, Paty BW, Lakey JR, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004; 53: 1311-7.

Eckhard M, Lommel D, Hackstein N, Winter D, Ziegler A, Rau W, et al. Disseminated periportal fatty degeneration after allogeneic intraportal islet transplantation in a patient with type 1 diabetes mellitus: a case report. Transplant Proc 2004; 36:1111-6.

Barshes NR, Lee TC, Goodpastor SE, Balkrishnan R,Schock AP, Mote A, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg 2005; 200: 353-61.

Contreras JL, Eckstein C, Smyth CA, Bilbao G, Vilatoba M, Ringland SE, et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004; 53: 2804-14.

Johansson H, Lukinius A, Moberg L, Lundgren T, Berne C, Foss A, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755-62.

Moberg L, Johansson H, Lukinius A, Berne C, Foss A,Källen R, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039-45.

Hyon SH, Ceballos MC, Barbich M, Groppa R,Grosembacher L, Vieiro MM, et al. Effect of the embolization of completely unpurified islets on portal vein pressure and hepatic biochemistry in clinical practice. Cell Transplant 2004; 13: 61-5.

Rafael E, Ryan EA, Paty BW, Oberholzer J, Imes S,Senior P, et al. Changes in liver enzymes after clinical islet transplantation. Transplantation 2003;76: 1280-4.

Casey JJ, Lakey JR, Ryan EA, Paty BW, Owen R,O'Kelly K, et al. Portal venous pressure changes after sequential clinical islet transplantation. Transplantation 2002; 74: 913-5.

Morrison CP, Wemyss-Holden SA, Dennison AR, Maddern GJ. Islet yield remains a problem in islet autotransplantation. Arch Surg 2002; 137:80-3.

Rafael E, Tibell A, Rydén M, Lundgren T, Sävendahl L, Borgström B, et al. Intramuscular autotransplantation of pancreatic islets in a 7-yearold child: a 2-year follow-up. Am J Transplant 2008;8: 458-62.

Miller R, Cirulli V, Diaferia GR, Ninniri S, Hardiman G,Torbett BE, et al. Switching-on survival and repair response programs in islet transplants by bone marrow-derived vasculogenic cells. Diabetes 2008;57: 2402-12.

Gao X, Song L, Shen K, Wang H, Niu W, Qin X.Transplantation of bone marrow derived cells promotes pancreatic islet repair in diabetic mice.Biochem Biophys Res Commun 2008; 371: 132-7.

Hasegawa Y, Ogihara T, Yamada T, Ishigaki Y, Imai J, Uno K, et al. Bone marrow (BM) transplantation promotes beta-cell regeneration after acute injury through BM cell mobilization. Endocrinology 2007;148: 2006-15.

Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes.Nature 2003; 422: 897-901.

Luo L, Badiavas E, Luo JZ, Maizel A. Allogeneic bone marrow supports human islet beta cell survival and function over six months. Biochem Biophys Res Commun 2007; 361: 859-64.

Mathews V, Hanson PT, Ford E, Fujita J, Polonsky KS, Graubert TA. Recruitment of bone marrow-derived endothelial cells to sites of pancreatic beta-cell injury. Diabetes 2004; 53: 91-8.

Li FX, Zhu JW, Tessem JS, Beilke J, Varella-Garcia M,Jensen J, et al. The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss. Proc Natl Acad Sci USA 2003;100:12935-12940.

Banerjee M, Kumar A, Bhonde RR. Reversal of experimental diabetes by multiple bone marrow transplantation. Biochem Biophys Res Commun 2005; 328: 318-25.

Izumida Y, Aoki T, Yasuda D, Koizumi T, Suganuma C, Saito K, et al. Hepatocyte growth factor is constitutively produced by donor-derived bone marrow cells and promotes regeneration of pancreatic beta-cells. Biochem Biophys Res Commun 2005; 333: 273-82.

Cantarelli E, Melzi R, Mercalli A, Sordi V, Ferrari G,Lederer CW, et al. Bone marrow as an alternative site for islet transplantation. Blood 2009 114: 4566-74.

Salazar-Bañuelos A, Wright JR Jr, Sigalet D, Benítez-Bribiesca L. Pancreatic islet transplantation into the bone marrow of the rat. Am J Surg 2008; 195: 674-8;discussion 678.

Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H,Beebe C, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988; 81: 435-41.

Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A,Nowotny P, et al. Insulin production rate following glucose ingestion estimated by splanchnic Cpeptide output in normal man. Diabetologia 1979;17: 221-7.

Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.Diabetes 2005; 54: 1649-56.

Lau J, Jansson L,Carlsson PO. Islets transplanted intraportally into the liver are stimulated to insulin and glucagon release exclusively through the hepatic artery. Am J Transplant 2006; 6: 967-75.

Zhou H, Zhang T, Bogdani M, Oseid E, Parazzoli S,Vantyghem MC, et al. Intrahepatic glucose flux as a mechanism for defective intrahepatic islet alphacell response to hypoglycemia. Diabetes 2008; 57:1567-74.

Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans. Diabetes 1997; 46:23-7.

Mattsson G, Jansson L, Nordin A, Andersson A,Carlsson PO. Evidence of functional impairment of syngeneically transplanted mouse pancreatic islets retrieved from the liver. Diabetes 2004; 53: 948-54.

Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ,Zajac AJ, Miller JD, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-87.





Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA